Drug Trial Radar · NCT05150587
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Last checked: Nov 20, 2026Latest source record: Apr 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
216
Actual
Start
Oct 5, 2021
Primary completion
Oct 20, 2022
Study completion Oct 20, 2022
Sponsor
- Lead sponsor
- Alfasigma S.p.A.Industry
- Sponsor type
- Industry
- Collaborators
- bioRASI, LLC
- First posted
- Dec 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes. Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particularly in those with papulopustular phenotype and positivity to Lactulose Breath Test (L-BT). The objective of this study is twofold: 1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults with moderate-to-severe papulopustular rosacea. 2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of patients.
Conditions
- Papulopustular Rosacea
Interventions
RifaximinDrug
Rifaximin tablets
PlaceboDrug
Placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory LesionsTime frame: 30 days
- Co-primary Endpoint: Treatment Success RateTime frame: 30 days
Locations
38 sites in 1 country. Site status is shown where the registry gives one.
Dermatology Research Ventures
Yuma, Arizona
Johnson Dermatology
Fort Smith, Arkansas
Long Beach Clinical Trials
Long Beach, California
Metropolis Dermatology
Los Angeles, California
LA Universal Research Center
Los Angeles, California
Cosmetic Laser Dermatology
San Diego, California
UCSD
San Diego, California
University Clinical Trials, Inc.
San Diego, California
Skin Care Research
Boca Raton, Florida
MOORE Clinical Research,Inc.
Brandon, Florida
Sweet Hope Research Specialty, Inc.
Hialeah, Florida
Savin Medical Group
Miami Lakes, Florida
Leavitt Medical Associates of Florida
Ormond Beach, Florida
DelRicht Research
Marietta, Georgia
DS Research
Clarksville, Indiana
Skin Science PLLC
Louisville, Kentucky
DS Research
Louisville, Kentucky
Delricht Research Baton Rouge LA
Baton Rouge, Louisiana
Delricht Research Covington LA
Covington, Louisiana
DelRicht Research Houma Louisiana
Houma, Louisiana
DelRicht Research
New Orleans, Louisiana
Revival Research Institute, LLC.
Troy, Michigan
Grekin Skin Care Institute
Wyandotte, Michigan
MediSearch Clinical Trials
Saint Joseph, Missouri
JDR Dermatology Research
Las Vegas, Nevada
JUVA Skin and Laser Center
New York, New York
Onsite Clinical Solutions
Charlotte, North Carolina
Dermatology Consulting Services, PLLC
High Point, North Carolina
DelRicht Research
Tulsa, Oklahoma
Oregon Dermatology and Research Center
Portland, Oregon
Paddington Testing Co, Inc
Philadelphia, Pennsylvania
Dermatology Treatment and Research Center
Dallas, Texas
3A Research
El Paso, Texas
DelRicht Research Frisco Texas
Frisco, Texas
Austin Institute for Clinical Research
Pflugerville, Texas
Progressive Clinical Research
San Antonio, Texas
Velocity Clinical Research
Salt Lake City, Utah
West End Dermatology Associates
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.